Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Malignant Melanoma

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 11 articles:
HTML format



Single Articles


    June 2020
  1. GUTZMER R, Stroyakovskiy D, Gogas H, Robert C, et al
    Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2020;395:1835-1844.
    PubMed     Abstract available


  2. RIBAS A
    Triple therapy for BRAF(V600)-mutated melanoma.
    Lancet. 2020;395:1814-1815.
    PubMed    


    May 2020
  3. ZIMMER L, Livingstone E, Hassel JC, Fluck M, et al
    Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet. 2020;395:1558-1568.
    PubMed     Abstract available


  4. SULLIVAN RJ
    Adjuvant nivolumab plus ipilimumab for resected stage IV melanoma.
    Lancet. 2020;395:1524-1525.
    PubMed    


    July 2019
  5. THOMPSON JF, Friedman EB
    Appropriate excision margins for cutaneous melanomas.
    Lancet. 2019 Jul 4. pii: S0140-6736(19)31272.
    PubMed    


  6. UTJES D, Malmstedt J, Teras J, Drzewiecki K, et al
    2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: long-term follow-up of a multicentre, randomised trial.
    Lancet. 2019 Jul 4. pii: S0140-6736(19)31132.
    PubMed     Abstract available


    March 2019
  7. JANUSZEWICZ W, Corrie P, Liu H, Chan J, et al
    A sinister black finding in the stomach.
    Lancet. 2019;393:1149.
    PubMed    


    September 2018
  8. SCHADENDORF D, van Akkooi ACJ, Berking C, Griewank KG, et al
    Melanoma.
    Lancet. 2018;392:971-984.
    PubMed     Abstract available


    June 2018
  9. LIU XK, Li J
    Acral lentiginous melanoma.
    Lancet. 2018;391:e21.
    PubMed    


    August 2017
  10. WISTUBA-HAMPRECHT K, Pawelec G
    KEYNOTE-006: a success in melanoma, but a long way to go.
    Lancet. 2017 Aug 16. pii: S0140-6736(17)31816.
    PubMed    


  11. SCHACHTER J, Ribas A, Long GV, Arance A, et al
    Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
    Lancet. 2017 Aug 16. pii: S0140-6736(17)31601.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: